Patent · US Active

1,4-oxazepines as BACE1 and/or BACE2 inhibitors

US8748418B2 · kind B2 · utility

1Cited by

0References

28Claims

0Family size

Assignee

Hoffmann-La Roche Inc. · US

Inventors

Emanuele Gabellieri · Lausanne, CH
Wolfgang Guba · Memmingen, DE
Hans Hilpert · Reinach, CH
Harald Mauser · Riehen, CH
Alexander V. Mayweg · Basel, CH
Mark Rogers-Evans · Bottmingen, CH
Didier Rombach · Mulhouse, FR
Andrew Thomas · Birsfelden, CH
Thomas Woltering · Freiburg (Elbe), DE
Wolfgang Wostl · Weil am Rhein, DE

Key dates

Filing date	Mar 9, 2012
Grant date	Jun 10, 2014
Priority date	—
Expiry date	Dec 4, 2032

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D413/12
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to 1,4-Oxazepines of formula Ihaving BACE1 and/or BACE2 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease and type 2 diabetes.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.